Q3 2024 West Pharmaceutical Services Inc Earnings Call Transcript

Oct 24, 2024 / 01:00 PM GMT

Release Date Price: MXN5969.08

Transcript 10-Q8-K

Key Points

Positve

West Pharmaceutical Services Inc (WST) reported solid third-quarter performance with revenues and adjusted EPS at the higher end of expectations.
The company increased its adjusted EPS guidance for the full year, reflecting confidence in its execution capabilities.
West Pharmaceutical Services Inc (WST) maintains a strong position in biologics, the fastest-growing segment within injectables.
The company is making meaningful investments to drive increased capacity, particularly in high-value products and contract manufacturing.
West Pharmaceutical Services Inc (WST) is seeing early traction with long-term growth initiatives, especially in GLP-1s and wearable self-injection devices.

Negative

West Pharmaceutical Services Inc (WST) experienced a low single-digit decline in organic sales and declines in operating profit and diluted EPS compared to the third quarter of 2023.
The company continues to face destocking challenges with some customers, particularly in the biologics and generics segments.
Adjusted operating profit margin decreased by 270 basis points from the same period last year.
The company recorded a decrease in operating cash flow for the nine months ended September 2024, primarily due to a decline in operating results.
West Pharmaceutical Services Inc (WST) anticipates continued destocking with some generic customers into 2025, indicating ongoing challenges in certain market segments.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

WST.N - West Pharmaceutical Services Inc
Q3 2024 West Pharmaceutical Services Inc Earnings Call
Oct 24, 2024 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
So yes, no, good day, and thank you for standing by. Welcome to the Q3 2020 for West Pharmaceutical Services Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question-and-answer session. To ask a question. During this session, you'll need to press star one on your telephone. You will then hear an automated message advising a hand iSeries. To withdraw your question, please press star one again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, John Sweeney, VP of Investor Relations, with was pharmaceuticals. Good morning and welcome to web Third Quarter

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.